Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study.

摘要

PurposeTo examine the safety and efficacy of zonisamide in treating myoclonic seizures associated with progressive myoclonic epilepsy (PME), in an open-label setting.MethodsThirty patients with refractory PME (aged >/= 5 years), who were taking up to three antiepileptic drugs, received adjunctive zonisamide (/= 50% decrease in myoclonic seizure frequency from baseline.ResultsTreatment-related AEs, experienced by 53% (n = 16/30) of patients, led to five patients discontinuing zonisamide. The most common AEs were decreased appetite, somnolence, and asthenia. Overall, 36% of patients (n = 10/28) had a >/= 50% reduction in myoclonic seizure frequency.ConclusionsThese results suggest that zonisamide may be useful in the treatment of patients with PME. However, due to the size and open-label character of this study, further research is required.